Oncimmune (LON:ONC)

Oncimmune (LON:ONC)


Share Price
92.50 p
Change
0 (0.00 %)
Market Cap
£58.51 m
Proactive Investors - Run By Investors For Investors

Oncimmune

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both immuno-oncology and autoimmune disease. Oncimmune is working to change how cancer is diagnosed and...

EPIC: ONC
Market: AIM:ONC
52-week High/Low: 138.50p / 77.00p
Sector: Pharma & Biotech
Market Cap: £58.51 m
Website: oncimmune.com
col 3
col 4
col 5
col 6

Oncimmune Snapshot

Current Products & Services:

EarlyCDT—Lung - a blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

EarlyCDT—Liver - a blood test to aid in the detection and confirmation of hepatocellular carcinoma (HCC), in association with imaging, in high-risk patients with liver lesions of all sizes.

Serotag Platform - Oncimmune’s proprietary biomarker discovery engine, which is used to discover and validate novel biomarkers that can help stratify different cancer indications and autoimmune diseases.

NavigAID for Autoimmune Disease - stratifies patients for improved therapeutic success based on the specific characteristics of their individual autoimmune disease, including the detection of biomarkers that are central to the disease’s pathology - autoantibodies.

NavigAID for Immuno-Oncology - able to detect autoantibodies for the prediction and monitoring of immune-related adverse events (irAEs), as well as therapeutic response for patients undergoing cancer immunotherapy, helping pharmaceutical and biotech companies develop safer, more effective immunotherapies.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as offices in London, UK and Shanghai, China.

Oncimmune has distribution in the folllowing countries:

Asia - China, Hong Kong, India, Korea, Singapore, Taiwan
EMEA - Denmark, France, Germany, Israel, Italy, Norway, Poland, Spain, Sweden, Turkey, UK
US

 

Dr Adam Hill | Chief Executive Officer

Dr. Adam M Hill MB PhD is a dual-qualified Clinician and Mechanical Engineer with a career built at the interface of industry, academia and health systems. Over the last 2 decades he has trained in surgery in the British Army; founded a successful applied research centre at Imperial College London; provided growth strategy and investment advice to global life science companies on behalf of the British Government; led the global medical function of a multinational, publicly-listed health IT company; and pivoted a Formula One team into a developer of health technology. Currently, Adam is a Visiting Professor in Global Health Innovation at Imperial College London, sits on the Value Creation Committee of Imperial College Health Partners and is Non Executive Director of Myrecovery.ai.

Adam graduated from Imperial College London as a Medical Doctor whilst also earning a PhD in Engineering, attending Imperial College Business School and the Royal Military Academy Sandhurst. He received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers.


Matthew Hall | Chief Financial Officer

Matthew Hall is a seasoned finance professional with over 25 years of corporate finance experience in a number of leading organisations and fast-growing companies. Matthew is a Chartered Accountant who initially spent 20 years as an investment banker with a focus on M&A as well as equity and debt funding for fast growing companies.

Over the past 10 years, Matthew has undertaken Chief Financial Officer roles for a number of life science companies, including, most recently CFO for Tusk Therapeutics, who was successfully divested for c.€650 million to Roche. Previously, Matthew was CFO at Sphere Medical Holding plc where he was appointed to lead the company’s successful IPO and prior to that was CFO of IS Pharma plc, where he was closely involved in the merger of IS Pharma plc and Sinclair Pharma plc.


Dr Andrea Murray | Chief Operational Scientist

Dr Murray has always had a passion for biological sciences. She studied Applied Biology at Nottingham Trent University before reading for a PhD in Pharmaceutical Sciences at the University of Nottingham. The focus of Dr Murray’s PhD studies was the development of monoclonal antibodies for diagnosis of cancer. She held a number of postdoctoral positions all within the fields of antibody technology and the diagnosis and treatment of cancer.

Dr Murray was awarded a travel fellowship by the European Association for Cancer Research which allowed her to spend a period of training at the Paul Scherrer Institute in Switzerland, where she worked on the development of techniques for conjugating radionuclides to biological molecules such as antibodies as a treatment for bladder cancer. Dr Murray has published over 50 papers in peer reviewed journals and has written several book chapters and invited reviews. She has presented her work at numerous national and international conferences.

When Dr Murray joined Oncimmune Limited in 2004 as Senior Director of Assay Development she was one of the Company’s first employees. Since then she has been involved with the EarlyCDT® platform through all of its stages of development and validation and has provided critical technical leadership since becoming Chief Operational Scientist in 2013.


Andrew Stewart | General Counsel & Company Secretary

Andrew Stewart BSc LLB, is a qualified barrister and solicitor (England and Australia) with deep experience in the healthcare industry. After building a career as a cross-border mergers and acquisitions lawyer with Clifford Chance, London and Minter Ellison, Melbourne, he held leadership roles in FTSE100 healthcare companies Smith & Nephew plc and Shire plc.

At London-listed Smith & Nephew plc, he led the legal team supporting the group’s global M&A efforts, closing transactions in markets as diverse as Colombia, Brazil and the US. He also led the legal team supporting European commercial operations and was a member of the commercial leadership team for Europe and Canada. Before that, Andrew was Chief Counsel M&A/Corporate at Shire Pharmaceuticals where he supported the many M&A transactions effected by Shire between 2003 and 2014, ranging from small management buy-outs, through technology licensing to multi-billion dollar public transactions.

Andrew graduated from Adelaide University with degrees in Science (Biochemistry, Immunology) and Law. He is admitted to practise law in England and Wales, Victoria and South Australia.

Shares Issued

As at 30th April 2019, the number of ordinary shares in issue was 63,250,217.

Major Shareholders

As at 30th April 2019, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company:

 

No of Ordinary Shares

%

Balderton Capital III, LP1

6,813,196

10.8

Genostics Company Ltd2

6,410,256

10.1

Richard Sharp

4,515,302

7.1

Ruffer LLP

3,334,239

5.3

Geoffrey Hamilton-Fairley

3,238,070

5.1

FIL Investment International

3,082,635

4.9

Timothy Bunting

2,806,717

4.4

Milton Asset Management

2,500,000

4.0

University of Nottingham

2,244,527

3.5

1 Mr Bunting is a partner of Balderton Capital (UK) LLP the investment adviser to Balderton Capital Partners III, LP.
2 Cheung To is a shareholder and director of Genostics Company Ltd.

 

Director Shareholdings

 

No of Shares

No of Share Options

No of Warrants

Tim Bunting

2,806,717

Geoffrey Hamilton-Fairley

3,238,070

798,148

762,500

Adam Hill

396,825

Richard Sharp

4,515,302

Meinhard Schmidt

420,370

226,250

 

Shares not in Public Hands

In accordance with the definition in the AIM Rules for Companies and insofar as it is aware, as at 30th April 2019, 39.47% of the Company’s AIM securities was not in public hands.

Restrictions on Transfer of Aim Securities

There are no restrictions on the transfer of securities.

UK City Code on Takeovers and Mergers

Oncimmune Holdings Plc is subject to the UK City Code on Takeovers and Mergers.

Details of Other Exchanges or Trading Platforms

Other than AIM, the Company’s shares are not admitted to or traded on any other exchanges or trading platforms.

Page last updated: 9th May 2019

Oncimmune Limited

Email: [email protected]

Phone: +44 (0)115 8231869

Clinical Sciences Building
Nottingham City Hospital
Hucknall Road
Nottingham
NG5 1PB
United Kingdom

Auditors

Grant Thornton UK LLP
Chartered Accountants, Statutory Auditor
Victoria House, 4th Floor
199 Avebury Boulevard
Milton Keynes
MK9 1AU

Solicitors to the Company

Peachey & Co LLP
95 Aldwych
London WC2B 4JF

Patent Attorneys to the Company

Boult Wade Tennant
Verulam Gardens
70 Gray’s Inn Road
London WC1X 8BT

Financial PR

Consilium Strategic Communications Limited
41 Lothbury
London EC2R 7HG

Company Registrars

Link Asset Services
34 Beckenham Road
Beckenham
Kent BR3 4TU

Columns Including ONC

VIEW ALL

Market Reports Including ONC

VIEW ALL

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use